» Articles » PMID: 38630096

Changes of Damage Associated Molecular Patterns in COVID-19 Patients

Overview
Date 2024 Apr 17
PMID 38630096
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The development of severe coronavirus disease 2019 (COVID-19) is associated with systemic hyperinflammation, which drives multi-organ failure and death. Disease deterioration tends to occur when the virus is receding; however, whether other factors besides viral products are involved in the inflammatory cascade remains unclear.

Methods: Twenty-eight COVID-19 patients with laboratory-confirmed SARS-CoV-2 infection hospitalized at the Fifth Medical Center of Chinese PLA General Hospital from January 23 to February 20, 2020 and nine healthy donors during the same period were recruited in the study. COVID-19 patients were grouped as mild, moderate, severe based on disease severity. Plasma damage-associated molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calprotectin (S100A8/A9), surfactant protein A (SP-A), cold-inducible RNA-binding protein (CIRBP), and Histone H4 were detected by ELISA assay, and analyzed in combination with clinical data. Plasma cytokines, chemokines and lymphocytes were determined by flow cytometry.

Results: Plasma levels of HMGB1 (38292.3 ± 4564.4 32686.3 ± 3678.1,  = 0.002), S100A8/A9 (1490.8 ± 819.3 742.2 ± 300.8,  = 0.015), and SP-A (6713.6 ± 1708.7 5296.3 ± 1240.4,  = 0.048) were increased in COVID-19 patients compared to healthy donors, while CIRBP (57.4 ± 30.7 111.9 ± 55.2,  = 0.004) levels decreased. Five DAMPs did not vary among mild, moderate, and severe patients. Moreover, SP-A levels correlated positively with inflammatory cytokines and negatively with time elapsed after symptom onset, whereas CIRBP showed an opposite pattern.

Conclusions: These findings suggest SP-A may involve in the inflammation of COVID-19, while CIRBP likely plays a protective role. Therefore, DAMPs represent a potential target in the prevention or treatment of COVID-19.

Citing Articles

Caspase-1 activation, IL-1/IL-6 signature and IFNγ-induced chemokines in lungs of COVID-19 patients.

Cambon A, Guervilly C, Delteil C, Potere N, Bachelier R, Tellier E Front Immunol. 2025; 15:1493306.

PMID: 39882243 PMC: 11774885. DOI: 10.3389/fimmu.2024.1493306.


Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies.

Heil M Front Immunol. 2024; 14:1259879.

PMID: 38439942 PMC: 10910434. DOI: 10.3389/fimmu.2023.1259879.


Temporal patterns of cytokine and injury biomarkers in hospitalized COVID-19 patients treated with methylprednisolone.

Mwangi V, Netto R, de Morais C, Silva A, Silva B, Lima A Front Immunol. 2023; 14:1229611.

PMID: 37662953 PMC: 10468998. DOI: 10.3389/fimmu.2023.1229611.


The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.

Wulandari S, Hartono , Wibawa T Immunology. 2022; 169(2):117-131.

PMID: 36571562 PMC: 9880760. DOI: 10.1111/imm.13623.


Serum concentration of extracellular cold-inducible RNA-binding protein is associated with respiratory failure in COVID-19.

Schagatay F, Diamant K, Liden M, Edin A, Athlin S, Hultgren O Front Immunol. 2022; 13:945603.

PMID: 35967397 PMC: 9373926. DOI: 10.3389/fimmu.2022.945603.


References
1.
Takahashi H, Kuroki Y, Tanaka H, Saito T, Kurokawa K, Chiba H . Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med. 2000; 162(1):258-63. DOI: 10.1164/ajrccm.162.1.9903014. View

2.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

3.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

4.
Zhang H, Xue J, Zhang Z, Kong H, Liu A, Li S . Cold-inducible RNA-binding protein inhibits neuron apoptosis through the suppression of mitochondrial apoptosis. Brain Res. 2015; 1622:474-83. DOI: 10.1016/j.brainres.2015.07.004. View

5.
Andersson U, Ottestad W, Tracey K . Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?. Mol Med. 2020; 26(1):42. PMC: 7203545. DOI: 10.1186/s10020-020-00172-4. View